Fuse Oncology Inc, a healthcare technology company focused on radiation oncology, announced on Monday that it has formed a strategic collaboration with Associated Medical Professionals of NY (AMP), an affiliate of U.S. Urology Partners, a General Atlantic company.
Under this collaboration AMP will run a proof of concept of FuseRx, a clinical workflow platform for radiation oncology, at its Center of Advanced Radiation Excellence in Syracuse.
Many large independent urology groups, including AMP, have brought radiation oncology in-house so that a patient is diagnosed, counselled and treated by one team. However, the workflow behind that care still runs across separate systems.
According to Fuse Oncology, FuseRx is built to take a patient from consult to treatment with the physician, physicist, dosimetrist, therapist and nurse working from one plan. The proof of concept at AMP starts with the physician's consult workflow -- the consult note and treatment intent, with the applicable ACRO pathway at the point of decision -- and will extend to the other roles as the full workflow rolls out over the coming months. FuseRx works with the EMR and oncology information system a practice already has.
INOVIO prices public offering of approximately USD75m
First patient dosed in Phase 1 trial of Transgene and BioInvent's BT-001 for rectal cancer
Elicera Therapeutics secures Chinese patent allowance for ELC-401
CHOSA Oncology signs US laboratory agreement for Platin-DRP commercialisation
BeOne Medicines wins FDA Priority Review for BRUKINSA combination in first-line mantle cell lymphoma
United Therapeutics eliminates Pfizer royalty obligations on ralinepag for USD525m
Pentixapharm advances preparationsfor Phase 3 PANDA study
ABIONYX Pharma partners with Lille University Hospital to explore CER-001 for severe burn patients
CStone and Kimia Therapeutics collaborate to advance oncology drug candidate
Merck launches Phase 3 trial of Ohtuvayre for COPD exacerbation prevention
Vivesto secures US orphan drug designation for Cantrixil in acute myeloid leukemia
Lytix Biopharma's ruxotemitide combination meets primary endpoint in Phase II melanoma trial